Geneva Capital Management LLC Sells 51,609 Shares of Certara, Inc. (NASDAQ:CERT)

Geneva Capital Management LLC lowered its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,458,600 shares of the company’s stock after selling 51,609 shares during the quarter. Geneva Capital Management LLC owned 3.39% of Certara worth $58,134,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of CERT. Harbor Capital Advisors Inc. lifted its position in Certara by 18.4% during the third quarter. Harbor Capital Advisors Inc. now owns 20,144 shares of the company’s stock valued at $236,000 after purchasing an additional 3,136 shares during the last quarter. Atria Investments Inc lifted its position in Certara by 21.6% during the third quarter. Atria Investments Inc now owns 19,743 shares of the company’s stock valued at $231,000 after purchasing an additional 3,501 shares during the last quarter. TimesSquare Capital Management LLC lifted its position in Certara by 3.1% during the third quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company’s stock valued at $11,202,000 after purchasing an additional 29,090 shares during the last quarter. Versor Investments LP bought a new position in Certara during the third quarter valued at $162,000. Finally, Oppenheimer Asset Management Inc. lifted its position in Certara by 6.8% during the third quarter. Oppenheimer Asset Management Inc. now owns 211,224 shares of the company’s stock valued at $2,473,000 after purchasing an additional 13,500 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

CERT has been the subject of several research reports. TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. Barclays increased their target price on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Finally, Stephens reissued an “overweight” rating and issued a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.83.

Certara Trading Up 0.5 %

CERT stock opened at $11.91 on Thursday. The company has a market capitalization of $1.92 billion, a PE ratio of -59.55, a P/E/G ratio of 9.29 and a beta of 1.60. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87. The firm’s 50-day moving average is $12.52 and its 200 day moving average is $11.63. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.